Immune Pharmaceuticals Inc (IMNP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
72
About the Report
About the Report
Summary
Immune Pharmaceuticals Inc (Immune Pharma), formerly EpiCept Corp is a drug development company that develops novel therapies for immunologic and inflammatory diseases. The company's pipeline products include Bertilimumab and Nanocyclo. Its Bertilimumab is a human monoclonal antibody designed to block the protein eotaxin-1 which causes various diseases. Immune Pharma's Nanocyclo is a nanoformulation of cyclosporine which enables the molecule to penetrate into the skin layers and provide local anti-inflammatory effect. The company also provides Crolibulin and Azixa, a novel small molecule vascular disrupting agent developed for the treatment of patients with solid tumors, primary brain cancers and metastatic tumors. Its products are used to treat bullous pemphigoid, ulcerative colitis, atopic dermatitis, psoriasis, and other inflammatory conditions. Immune Pharma develops drugs in the areas of immuno-oncology, nano-dermatology and neuropathic pain. The company has operations in the US and Israel. Immune Pharma is headquartered in Englewood Cliffs, New Jersey, the US.
Immune Pharmaceuticals Inc (IMNP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Immune Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Immune Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 14
Partnerships 14
WuXi Biologics and Immune Pharma Enter into Co-Development Agreement 14
Immune Pharma Enters into Agreement with STC Biologics 15
Immune Pharma Plans to Partner with Hebrew University of Jerusalem 16
Immune Pharma Enters Into Co-Development Agreement With Yeda Research 17
Licensing Agreements 18
Immune Pharmaceuticals Enters into Licensing Agreement with Pint Pharma 18
SATT Sud Est Enters into Licensing Agreement with Immune Pharma 19
Maxim Pharma Enters into Licensing Agreement with Immune Pharma 20
Novel Pain Therapeutics Amends Option for Licensing Agreement with Immune Pharma 21
Immune Pharma Enters into Licensing Agreement with BioNanoSim 22
Immune Pharma Enters into Licensing Agreement with Yissum 23
Immune Pharma to Enter into Licensing Agreement with Yissum Research Development 25
Lonza Sales Enters into Licensing Agreement with Immune Pharma for Bertilimumab 26
Equity Offering 27
Immune Pharma Raises USD18 Million in Public Offering of Units 27
Immune Pharma Plans to Raise up to USD2.5 Million in Public Offering of Shares 29
Immune Pharma to Spin-off its Cytovia 30
Immune Pharma Plans to Raise up to USD3 Million in Public Offering of Shares 31
Immune Pharma Raises USD2 Million in Share Purchase Plan 32
Maxim Pharma to Raise upto USD20 Million in Private Placement of Shares 33
Immune Pharma Completes Spin Off of Pain and Neurology Business 34
Immune Pharma Raises USD1 Million in Private Placement of Shares 35
Immune Pharma Raises USD0.8 Million in Private Placement of Shares 36
Immune Pharma Raises USD1 Million in Private Placement of Shares 37
Immune Pharmaceuticals Raises USD9 Million in Private Placement of Series D Redeemable Convertible Preferred Stock 38
Immune Pharma Completes Underwriters Exercise of Partial Over-Allotment Option of Public Offering of Units for USD9.7 Million 40
Immune Pharma Raises USD1 Million in Private Placement of Units 41
Immune Pharma Raises USD11.7 Million in Private Placement of Units and Warrants 42
Debt Offering 43
Immune Pharma Raises USD1.5 Million in First Tanche of Private Placement of Debentures 43
Immune Pharma Raises USD0.5 Million in Private Placment of 6% Notes Due 2018 44
Immune Pharma Raises USD1 Million in Private Placement of Convertible Notes 45
Acquisition 46
Immune Pharma Completes Acquisition Of EpiCept In Reverse Takeover Transaction 46
Immune Pharmaceuticals Inc-Key Competitors 48
Immune Pharmaceuticals Inc-Key Employees 49
Immune Pharmaceuticals Inc-Locations And Subsidiaries 50
Head Office 50
Other Locations & Subsidiaries 50
Recent Developments 51
Strategy And Business Planning 51
Jul 19, 2017: Immune Pharmaceuticals Provides Update on Plan to Implement a Spin-off of Cytovia into a Separate Publicly Traded Oncology Company 51
Financial Announcements 52
Apr 02, 2018: Immune Pharmaceuticals Announces 2017 Financial Results 52
Nov 15, 2017: Immune Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides a Corporate Update 54
Aug 28, 2017: Immune Pharmaceuticals Provides Business Update and Summary of Recent Financial Highlights 56
Corporate Communications 57
Nov 27, 2017: Immune Provides Update Regarding NASDAQ US Listing and Departure of Officer 57
Aug 29, 2017: Immune Pharmaceuticals Receives NASDAQ Letter 58
Aug 14, 2017: Immune Pharmaceuticals Appoints Tony Fiorino, MD, PhD as Chief Medical Officer and Chief Operating Officer 59
Jun 19, 2017: Immune Receives NASDAQ Compliance Letter 60
May 26, 2017: Immune Receives Nasdaq Letters 61
Apr 24, 2017: Immune Receives Nasdaq Letter 62
Mar 13, 2017: Immune Pharmaceuticals Granted Additional Time to Comply with Nasdaq Listing Requirement 63
Jan 27, 2017: Immune Pharmaceuticals Appoints New Chairman of the Board of Directors 64
Government and Public Interest 65
Apr 24, 2017: Immune Pharmaceuticals Announces Corporate Restructuring 65
Other Significant Developments 66
Feb 20, 2018: Immune Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders and Provides Business Update 66
Aug 04, 2017: Immune Pharmaceuticals Issues Letter to Shareholders 69
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72
List of Figure
List of Figures
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Immune Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
List of Table
List of Tables
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Immune Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 10
Immune Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
WuXi Biologics and Immune Pharma Enter into Co-Development Agreement 14
Immune Pharma Enters into Agreement with STC Biologics 15
Immune Pharma Plans to Partner with Hebrew University of Jerusalem 16
Immune Pharma Enters Into Co-Development Agreement With Yeda Research 17
Immune Pharmaceuticals Enters into Licensing Agreement with Pint Pharma 18
SATT Sud Est Enters into Licensing Agreement with Immune Pharma 19
Maxim Pharma Enters into Licensing Agreement with Immune Pharma 20
Novel Pain Therapeutics Amends Option for Licensing Agreement with Immune Pharma 21
Immune Pharma Enters into Licensing Agreement with BioNanoSim 22
Immune Pharma Enters into Licensing Agreement with Yissum 23
Immune Pharma to Enter into Licensing Agreement with Yissum Research Development 25
Lonza Sales Enters into Licensing Agreement with Immune Pharma for Bertilimumab 26
Immune Pharma Raises USD18 Million in Public Offering of Units 27
Immune Pharma Plans to Raise up to USD2.5 Million in Public Offering of Shares 29
Immune Pharma to Spin-off its Cytovia 30
Immune Pharma Plans to Raise up to USD3 Million in Public Offering of Shares 31
Immune Pharma Raises USD2 Million in Share Purchase Plan 32
Maxim Pharma to Raise upto USD20 Million in Private Placement of Shares 33
Immune Pharma Completes Spin Off of Pain and Neurology Business 34
Immune Pharma Raises USD1 Million in Private Placement of Shares 35
Immune Pharma Raises USD0.8 Million in Private Placement of Shares 36
Immune Pharma Raises USD1 Million in Private Placement of Shares 37
Immune Pharmaceuticals Raises USD9 Million in Private Placement of Series D Redeemable Convertible Preferred Stock 38
Immune Pharma Completes Underwriters Exercise of Partial Over-Allotment Option of Public Offering of Units for USD9.7 Million 40
Immune Pharma Raises USD1 Million in Private Placement of Units 41
Immune Pharma Raises USD11.7 Million in Private Placement of Units and Warrants 42
Immune Pharma Raises USD1.5 Million in First Tanche of Private Placement of Debentures 43
Immune Pharma Raises USD0.5 Million in Private Placment of 6% Notes Due 2018 44
Immune Pharma Raises USD1 Million in Private Placement of Convertible Notes 45
Immune Pharma Completes Acquisition Of EpiCept In Reverse Takeover Transaction 46
Immune Pharmaceuticals Inc, Key Competitors 48
Immune Pharmaceuticals Inc, Key Employees 49
Immune Pharmaceuticals Inc, Other Locations 50
Immune Pharmaceuticals Inc, Subsidiaries 50
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.